regadenoson (Lexiscan)
Jump to navigation
Jump to search
Indications
- stress agent for patients unable to undergo exercise stress testing (myocardial perfusion scintigraphy) Contradindications:
- may cause bronchospasm, use with caution in patients with asthma or COPD*
* according to[4] (NEJM) regadenoson may be used in patients with stable COPD without active bronchospasm
Adverse effects
- rare but serious risk of myocardial infarction & death[3]
Mechanism of action
- presumptively vasodilator (by analogy to persantine)
Notes
Manufacturer: Astellas Pharma
More general terms
References
- ↑ Prescriber's Letter 16(2): 2009 New Drugs Approved by the FDA in 2008 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=250213&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ Al Jaroudi W, Iskandrian AE. Regadenoson: a new myocardial stress agent. J Am Coll Cardiol. 2009 Sep 22;54(13):1123-30 PMID: https://www.ncbi.nlm.nih.gov/pubmed/19761931
- ↑ 3.0 3.1 FDA MedWatch. Nov 20, 2013 Lexiscan (regadenoson) and Adenoscan (adenosine): Drug Safety Communication - Rare but Serious Risk of Heart Attack and Death. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm375981.htm
- ↑ 4.0 4.1 NEJM Knowledge+ Complex Medical Care